Advisory #428 notes these medications are administered in a hospital setting only by trained healthcare professionals.
What comes to mind when you think about the future?
The cooperative agreement supports education and awareness programs for bleeding disorders patients, family members, and providers.
BioMarin plans to meet with the FDA in the coming weeks to align on the next steps to obtain approval.
Concizumab is an investigational therapy designed to be equally effective in individuals with hemophilia A and B, irrespective of inhibitor status
The recall has been expanded from the pharmacy level to the patient, or consumer level.
Ferring has extended the recall of Stimate to the consumer level.
NHF's Medical and Scientific Advisory Council (MASAC) discussed the role of people with bleeding disorders in SARS-CoV-2 Treatment and Vaccine Trials at NHF's virtual Bleeding Disorders Conference.
The private, online community is for Black and African Americans with bleeding disorders, their family members, and support network.
CSL Behring and Ferring Pharmaceuticals, Inc have responded to the joint NHF-NHF letter of July 22, 2020, regarding a recent recall of Stimate (desmopressin) nasal spray.
eNewsletter Sign Up
Steps for Living
Victory for Women
Unite for Bleeding Disorders Walk
Donate Your Car